<DOC>
	<DOC>NCT00088491</DOC>
	<brief_summary>This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine; evaluate different doses of IM olanzapine depot; and determine the blood levels of IM olanzapine depot in patients at different points in time after an injection.</brief_summary>
	<brief_title>Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients must have schizophrenia Patients must be clinically stable on antipsychotic medication Patients must be retrospectively judged by investigators, based on clinical interview and impression, to have been stable (with respect to their symptoms of schizophrenia) for at least 4 weeks entry into the study Patients must be an outpatient and have BPRS positive items scores of 4 or less to enter the study Female patients of childbearing potential must be using a medically accepted means of contraception. Patients must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry. Female patients must not be pregnant or breastfeeding Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia Patients must not require concomitant treatment with any other medication with primarily central nervous system activity, including antidepressants, mood stabilizers, and anticonvulsants. Patients must not have a substance (except nicotine or caffeine) dependence within the past 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>